PBYI - Puma Biotechnology wins extension for U.S. patent related to breast cancer therapy

Puma Biotechnology (NASDAQ:PBYI) announced that the U.S. regulators have extended the term of a patent related to the company’s breast cancer therapy NERLYNX by five years. The United States Patent and Trademark Office (USPTO) has extended the validity period of U.S. Patent No. 7,399,865. With the decision, the patent covering the claims for the composition of matter for NERLYNX will now expire on December 29, 2030. “This will allow us to invest further in the drug to look at additional ways that the drug can continue to help cancer patients,” CEO Alan H. Auerbach remarked. A kinase inhibitor, NERLYNX tablets, are allowed as a single agent or in combination with capecitabine for adults with HER2-positive breast cancer. The company’s net product revenue, comprised entirely of NERLYNX, dropped ~12% YoY to $43.4M in Q3 2021.

For further details see:

Puma Biotechnology wins extension for U.S. patent related to breast cancer therapy